| 中文名 | OICR-9429 |
|---|---|
| 英文名 | oicr-9429 |
| 中文别名 |
N-(4-(4-甲基哌嗪-1-基)-3'-(吗啉代甲基)- [1,1'-联苯] -3-基)-6-氧代-4-(三氟甲基)-1,6-二氢吡啶-3-甲酰胺
抑制剂OICR-9429 N-(4-(4-甲基哌嗪-1-基)-3'-(吗啉代甲基)-[1,1'-联苯]-3-基)-6-氧代-4-(三氟甲基)-1,6-二氢吡啶-3-甲酰胺 6-羟基-N-(4-(4-甲基哌嗪-1-基)-3-(吗啉代甲基)-[1,1-二联苯]-3-基)-4-(三氟甲基)尼克酰胺 OICR 9429,WDR5拮抗剂 |
| 英文别名 |
3-Pyridinecboxamide, 1,6-dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]-6-oxo-4-(trifluoromethyl)
N-[4-(4-Methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)-3-biphenylyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxamide N-[4-(4-Méthyl-1-pipérazinyl)-3'-(4-morpholinylméthyl)-3-biphénylyl]-6-oxo-4-(trifluorométhyl)-1,6-dihydro-3-pyridinecarboxamide N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-cboxamide N-[2-(4-Methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-cboxamide 6-hydroxy-N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide OICR-9429 N-[4-(4-Methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)-3-biphenylyl]-6-oxo-4-(trifluormethyl)-1,6-dihydro-3-pyridincarboxamid OICR9429,pancreatic,Histone Methyltransferase,MLL,inhibit,OICR-9429,colon,prostate cance,bladder cancer (BCa),Inhibitor,WD reat domain 5 (WDR5),Apoptosis,leukaemia,H3K4 OICR-9429 (OICR9429 N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1H-pyridine-3-cboxamide OICR-9429, 10 mM in DMSO OICR9429 |
| 描述 | OICR-9429是一个新颖的相互作用的小分子Wdr5-MLL拮抗剂,IC50是5 uM,能够抑制增殖。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 密度 | 1.3±0.1 g/cm3 |
|---|---|
| 沸点 | 693.0±55.0 °C at 760 mmHg |
| 分子式 | C29H32F3N5O3 |
| 分子量 | 555.591 |
| 闪点 | 372.9±31.5 °C |
| 精确质量 | 555.245728 |
| LogP | 1.84 |
| 外观性状 | 粉末 |
| 蒸汽压 | 0.0±2.2 mmHg at 25°C |
| 折射率 | 1.602 |
| 储存条件 | -20℃ |